Page 3 - Zyme Communications News Today

Funding will support the development of Aurase Wound Gel and progress toward further Phase II clinical trials of innovative wound debriding enzyme SOLASCURE Ltd (SolasCure), a biotechnology company

Services support peptide purification, custom synthesis of PEC-grade peptides, and development and production of peptide drugs and drug candidates PurePep EasyClean (PEC) orthogonal purification

Investegate announcements from Avacta Group PLC, Issue of Equity and Total Voting Rights

Oversubscribed round led by Foresite Capital Funding will enable development of DNA synthesis chip technology to commercial scale EVONETIX LTD ('Evonetix'), the synthetic biology company

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a multi target Research Agreement with Endevica Bio Inc., (Endevica), a company

New company created to enable commercial manufacture of new cell and gene therapies Cellular Origins' proprietary technology will address current barriers associated with cost-effective and

Expansion of five-year collaboration broadens established Organ-on-a-chip research demonstrating advanced performance of the PhysioMimix MPS New research project to investigate the use of

Positive safety profile of AVA6000 continues in the fourth cohort Analysis of six tumour biopsies confirms the tumour targeting potential of pre|CISION technology Avacta Group plc (AIM: AVCT)

Preclinical program with potential for disease modifying therapeutic Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that

Orbit Discovery Limited (Orbit), a leader in the discovery of therapeutic peptide hits, today announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company